About This Trial

Antibody-drug conjugate targeting Trop2 with novel topoisomerase I inhibitor payload.

Primary Endpoints

  • Progression-free survival
  • Overall survival

Latest Update

February 2026

Met primary PFS endpoint with 6.9 month improvement vs chemotherapy. FDA filing imminent.